Erica Simone Dayan

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy”.

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies

JCO Oncology Practice(2022)10.1200/op.21.00816

N/A

0DataRank · unranked

11 citations

Erica Simone Dayan, Niamh M. Keegan, Abigail Bacharach, Sungmin Woo, Theresa A. Gillis +2 more

Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5026

N/A

0DataRank · unranked

0 citations

Andrea Arfè, Ethan Barnett, Erica Simone Dayan, Jimmy L. Zhao, Emily Carbone +5 more

Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-23-9

N/A

0DataRank · unranked

5 citations

Justine Anderson, Daniel C. Danila, Michael J. Morris, Susan F. Slovin, Wassim Abida +5 more